Amgen Stock Rises as Market Awaits Next Catalyst

Amgen's (AMGN) stock has been rising since management raised its full-year revenue guidance on August 4. The company points to six key growth drivers that collectively grew at a 26% year-over-year clip and now account for nearly 70% of product sales.

The real excitement lies in Amgen's late-stage pipeline, particularly MariTide, an experimental obesity drug designed for monthly therapy with the potential for as few as 4 or 6 doses per year. This could be a game-changer in a field crowded with weekly injections, but it's a high-wire act.

Traders are pricing in an unusual amount of turbulence, with Amgen's implied volatility sitting at 30%, which is in the 93rd percentile of its one-year range. Options are expensive because the market expects a big move around the next major catalyst, whether it's an earnings report or a pipeline update.